P766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED ANALYSIS

• A. M. Zeidan,
• E. S. Mearns,
• C. Ng,
• A. Shah,
• N. Lamarre,
• A. Yellow-Duke,
• N. Alrawashdh,
• B. Yang,
• W. Cheng,
• C. N. Bui,
• A. Svensson

Affiliations

A. M. Zeidan

1 Yale Cancer Center, Yale University School of Medicine, New Haven

E. S. Mearns

2 Genentech, Inc., South San Francisco

C. Ng

2 Genentech, Inc., South San Francisco

A. Shah

2 Genentech, Inc., South San Francisco

N. Lamarre

3 Real World Data Analytics, Genesis Research, Hoboken

A. Yellow-Duke

2 Genentech, Inc., South San Francisco

N. Alrawashdh

2 Genentech, Inc., South San Francisco

B. Yang

4 Roche Diagnostics, Santa Clara

W. Cheng

5 AbbVie, North Chicago, United States of America

C. N. Bui

5 AbbVie, North Chicago, United States of America

A. Svensson

5 AbbVie, North Chicago, United States of America